Inozyme Pharma, Inc.: key financial figures for fiscal year 2024 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:
- Net Income/Loss (FY2024)
- -$102.0M
- Total Assets (FY2024)
- $123.2M
- Total Equity (FY2024)
- $57.8M
- Cash Flows from Operating Activities (FY2024)
- -$91.9M
Source: Inozyme Pharma, Inc. 10-K filing (FY2024). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.
